In the present study, we characterized the association between classic driver oncogene mutations in East Asian NSCLC patients and the efficacy of anti-PD-1/PD-L1 immunotherapy, in addition to tumor immunity-associated features such as PD-L1 expression, the presence of CD8+ TIL, and the intratumoral immune cell composition. Here, CD8A is linked to non-small cell lung carcinoma.